Literature DB >> 17109565

Prescribing antiepileptics for the elderly: differences between guideline recommendations and clinical practice.

Mary Jo V Pugh1, Perry J Foreman, Dan R Berlowitz.   

Abstract

The incidence of epilepsy in patients aged >60 years is higher than in any other period of life. Yet, until recently, what was known about the treatment of older patients with epilepsy has been inferred from studies in younger patients. A growing body of clinical evidence focused exclusively on the elderly suggests that, while some issues are similar for older and younger adults, older patients with epilepsy may require even more attention regarding antiepileptic drug (AED) selection than younger patients. This article reviews published guidelines and recommendations to identify explicit recommendations for use of specific AEDs in the elderly, and assesses the extent to which those recommendations have been adopted in clinical practice. We found that while one systematically derived guideline stated that lamotrigine may be a good choice for older patients because of its favourable adverse effect profile, only clinical recommendations based on expert opinion explicitly identified AEDs that are more and less appropriate for use in the elderly. Examination of published studies describing recent AED-prescribing patterns suggests that clinical recommendations have been, at best, slowly adopted. This observation is exemplified by the fact that older patients newly diagnosed with epilepsy are still prescribed phenobarbital--a drug identified as suboptimal in 1985. In order to better understand the delay in adopting clinical recommendations, we examine these findings in light of diffusion of innovations theory, a theory that has been used to understand dissemination of other new medical technologies. According to this theory, while it is too early to suggest that use of second-generation AEDs in the elderly has been delayed, the continued use of phenobarbital in older patients newly diagnosed with epilepsy represents a serious delay in adoption of recent guidelines. Delays may be related to lack of knowledge by primary care clinicians and emergency room physicians (who frequently treat older patients with epilepsy), lack of 'opinion leaders' in primary care and perhaps general neurology, clinicians' focus on seizure control as the primary endpoint in treating patients with epilepsy, and difficulties in changing long-standing prescribing patterns. Research targeting barriers to more appropriate prescribing is needed to determine appropriate strategies for changing AED prescribing practices in the elderly.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17109565     DOI: 10.2165/00002512-200623110-00002

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  59 in total

1.  Randomized dose-controlled study of topiramate as first-line therapy in epilepsy.

Authors:  S Arroyo; W E Dodson; M D Privitera; T A Glauser; D K Naritoku; D J Dlugos; S Wang; S K Schwabe; R E Twyman
Journal:  Acta Neurol Scand       Date:  2005-10       Impact factor: 3.209

2.  Effectiveness of first antiepileptic drug.

Authors:  P Kwan; M J Brodie
Journal:  Epilepsia       Date:  2001-10       Impact factor: 5.864

3.  Results of a nationwide Veterans Administration Cooperative Study comparing the efficacy and toxicity of carbamazepine, phenobarbital, phenytoin, and primidone.

Authors:  D B Smith; R H Mattson; J A Cramer; J F Collins; R A Novelly; B Craft
Journal:  Epilepsia       Date:  1987       Impact factor: 5.864

Review 4.  The importance of drug interactions in epilepsy therapy.

Authors:  Philip N Patsalos; Walter Fröscher; Francesco Pisani; Clementina M van Rijn
Journal:  Epilepsia       Date:  2002-04       Impact factor: 5.864

Review 5.  Initial treatment of epilepsy: special issues in treating the elderly.

Authors:  Gregory K Bergey
Journal:  Neurology       Date:  2004-11-23       Impact factor: 9.910

Review 6.  What we don't learn from clinical trials in epilepsy.

Authors:  Frank Gilliam
Journal:  Epilepsia       Date:  2003       Impact factor: 5.864

7.  Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures.

Authors:  R H Mattson; J A Cramer; J F Collins; D B Smith; A V Delgado-Escueta; T R Browne; P D Williamson; D M Treiman; J O McNamara; C B McCutchen
Journal:  N Engl J Med       Date:  1985-07-18       Impact factor: 91.245

8.  A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. The Department of Veterans Affairs Epilepsy Cooperative Study No. 264 Group.

Authors:  R H Mattson; J A Cramer; J F Collins
Journal:  N Engl J Med       Date:  1992-09-10       Impact factor: 91.245

Review 9.  Clinical pharmacokinetic considerations in the elderly. An update.

Authors:  S Dawling; P Crome
Journal:  Clin Pharmacokinet       Date:  1989-10       Impact factor: 6.447

10.  Gabapentin versus lamotrigine monotherapy: a double-blind comparison in newly diagnosed epilepsy.

Authors:  Martin J Brodie; David W Chadwick; Henning Anhut; Andreas Otte; Silke-Lo Messmer; Stephen Maton; Wilhelm Sauermann; Guta Murray; Elizabeth A Garofalo
Journal:  Epilepsia       Date:  2002-09       Impact factor: 5.864

View more
  8 in total

1.  The 'apparent clearance' of free phenytoin in elderly vs. younger adults.

Authors:  Daniel F B Wright; Evan J Begg
Journal:  Br J Clin Pharmacol       Date:  2010-07       Impact factor: 4.335

2.  Antiepileptic Drug Treatment in Community-Dwelling Older Patients with Epilepsy: A Retrospective Observational Study of Old- Versus New-Generation Antiepileptic Drugs.

Authors:  Jacques Theitler; Anna Brik; Dotan Shaniv; Matitiahu Berkovitch; Revital Gandelman-Marton
Journal:  Drugs Aging       Date:  2017-06       Impact factor: 3.923

3.  Knowledge of the pharmacological profile of a patient improves the quality of prescribing, the outcomes of treatment, and the utilization of health services in primary health care.

Authors:  Srdjan M Stefanovic; Slobodan M Jankovic
Journal:  Eur J Clin Pharmacol       Date:  2011-05-14       Impact factor: 2.953

4.  Prospective evaluation of a post-stroke epilepsy risk scale.

Authors:  Adam Strzelczyk; Anja Haag; Hans Raupach; Gregor Herrendorf; Hajo M Hamer; Felix Rosenow
Journal:  J Neurol       Date:  2010-03-23       Impact factor: 4.849

5.  What does the U.S. Medicare administrative claims database tell us about initial antiepileptic drug treatment for older adults with new-onset epilepsy?

Authors:  Roy C Martin; Edward Faught; Jerzy P Szaflarski; Joshua Richman; Ellen Funkhouser; Kendra Piper; Lucia Juarez; Chen Dai; Maria Pisu
Journal:  Epilepsia       Date:  2017-02-07       Impact factor: 5.864

6.  Changes in the Use of Brand Name and Generic Medications and Total Prescription Cost Among Medicare Beneficiaries With Epilepsy.

Authors:  Samuel Waller Terman; Chun C Lin; Wesley T Kerr; Lindsey B DeLott; Brian C Callaghan; James F Burke
Journal:  Neurology       Date:  2022-06-15       Impact factor: 11.800

Review 7.  Utilization and costs of antiepileptic drugs in the elderly: still an unsolved issue.

Authors:  Massimiliano Beghi; Rodolfo Savica; Ettore Beghi; Alessandro Nobili; Livio Garattini
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

8.  Effects of lamotrigine on mood in older adults with epilepsy and co-morbid depressive symptoms: an open-label, multicentre, prospective study.

Authors:  Toufic A Fakhoury; J Mitchell Miller; Anne E Hammer; Alain Vuong
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.